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http://dx.doi.org/10.1016/j.stemcr.2016.07.016SUMMARYWhen comparing hepatic phenotypes between iPSC-derived hepatocyte-like cells from different liver disease patients, cell heterogeneity
can confound interpretation. We proposed that homogeneous cell populations could be generated by fluorescence-activated cell sorting
(FACS). Using cell-surface capture proteomics, we identified a total of 300 glycoproteins on hepatocytes. Analyses of the expression
profiles during the differentiation of iPSCs revealed that SLC10A1, CLRN3, and AADAC were highly enriched during the final stages
of hepatocyte differentiation. FACS purification of hepatocyte-like cells expressing SLC10A1, CLRN3, or AADAC demonstrated enrich-
ment of cells with hepatocyte characteristics. Moreover, transcriptome analyses revealed that cells expressing the liver gene regulatory
networkwere enrichedwhile cells expressing a pluripotent stem cell networkwere depleted. In conclusion,we report an extensive catalog
of cell-surfaceN-linked glycoproteins expressed in primary hepatocytes and identify cell-surface proteins that facilitate the purification of
homogeneous populations of iPSC-derived hepatocyte-like cells.INTRODUCTION
Directed differentiation of pluripotent stem cells (PSCs) to
cells of a specific fate holds promise to study a wide variety
of human diseases (Robinton and Daley, 2012). Several
groups have reported the generation of hepatocyte-like
cells from human PSCs by the sequential addition of
growth factors (Agarwal et al., 2008; Basma et al., 2009;
Cai et al., 2007; Hay et al., 2008; Song et al., 2009; Si-Tayeb
et al., 2010a; Sullivan et al., 2010). The cells produced by
these approaches share many characteristics with primary
hepatocytes, although transcriptional profiling has sug-
gested that the cells in general tend to be less mature
than their native counterparts (Si-Tayeb et al., 2010a).
Nevertheless, induced PSCs (iPSCs) derived from patients
with inborn errors in hepatic metabolism have been used
to successfully model several liver diseases in culture
(Rashid et al., 2010; Cayo et al., 2012; Choi et al., 2013;
Tafaleng et al., 2015). Most of the liver diseases that have
been successfully modeled originate from patients with
Mendelian inherited mutations that show robust pheno-
types. Examples include familial hypercholesterolemia
and a-1-antitrypsin deficiency, which are caused by muta-
tions in the LDLR (Low-Density Lipoprotein Receptor) and
SERPINA1 (Serpin Peptidase Inhibitor, Clade A [Alpha-1 Anti-
proteinase, Antitrypsin], Member 1) genes, respectively (Ra-
shid et al., 2010; Cayo et al., 2012; Tafaleng et al., 2015;
Choi et al., 2013). While such successes are encouraging,Stem Cell Repo
This is an open access artiit has become clear that complex traits and subtle pheno-
types are more challenging to reproduce, primarily due to
variations in the efficiency of differentiation among
cells. Most, if not all, differentiation protocols generate
iPSC-derived hepatocyte-like cells with heterogeneous
expression of mature hepatic markers.
The generation of antibodies that facilitate purification
of homogeneous subpopulations of cells has significantly
advanced the study of lymphoid lineages and hematopoi-
etic stem cells (Lanier et al., 1983; Spangrude et al., 1988).
More recently, similar approaches have been used to iden-
tify and characterize subpopulations of liver cells in mice
with progenitor cell characteristics (Dorrell et al., 2008,
2011). Antibodies that recognize cell-surface antigens
have historically been generated by immunization of re-
cipient animals with whole cells or membrane fractions.
Antibodies that specifically recognize a given cell type are
then identified by secondary screens. This procedure has
recently been used successfully to identify monoclonal
antibodies that can detect iPSC-derived endoderm cells
that have an enhanced propensity to adopt a hepatic fate
(Holtzinger et al., 2015). Although such an approach has
been invaluable, the nature of the antigen can be complex
and identification of epitopes challenging.
As an alternative to antibody-based methods, we used
the chemoproteomic cell surface capture technology
(CSC-Technology; Wollscheid et al., 2009; Gundry et al.,
2012), which incorporates selective labeling, enrichment,rts j Vol. 7 j 543–556 j September 13, 2016 j ª 2016 The Author(s). 543
cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Identification of Cell-Surface
Proteins for Purifying a Subpopulation
of iPSC-Derived Hepatocyte-like Cells
A schematic overview of the approach used
to identify cell-surface N-glycoproteins and
candidate markers for hepatocyte sorting.
Proteomic and oligonucleotide array ana-
lyses were combined to identify cell-surface
N-glycoproteins that are enriched in hepa-
tocyte-like cells that are derived from iPSCs.and mass-spectrometry-based identification of extracel-
lular domains of cell-surface N-glycoproteins to discover
accessible surface markers on human hepatocytes. By es-
tablishing a ‘‘surfaceome’’ of human hepatocytes, this
resource reveals targets for fluorescence-activated cell sort-
ing (FACS)-based isolation, contributes to our knowledge of
N-glycoproteins that define the hepatocyte phenotype,
and is a first step toward revealing N-glycoproteins with
potentially important roles in hepatocyte function and
disease. Using a combination of proteomic and transcrip-
tional profiling along with antibody-based sorting, we re-
vealed that SLC10A1, CLRN3, and AADAC are cell-surface
N-glycoproteins that are present on a common population
of iPSC-derived hepatocyte-like cells that express elevated
levels of several hepatic markers. Transcriptional profiling
of purified SLC10A1-positive cells revealed enrichment of
hepatic character, improved homogeneity, and depletion
of cells expressing pluripotent markers.RESULTS
Cell-Surface N-Glycoproteins on Primary Human
Hepatocytes
To identify cell-surface N-glycoproteins that could poten-
tially be used to purify homogeneous populations of
iPSC-derived hepatocytes, we incorporated proteomic and
transcriptomic analyses of primary hepatocytes and iPSC-
derived cells (Figure 1). We first used the CSC-Technology
to identify extracellular domains of cell-surface N-glyco-544 Stem Cell Reports j Vol. 7 j 543–556 j September 13, 2016proteins on primary human hepatocytes. This approach
(Figure 2A) exploits biotinylation of the oligosaccharide
structure attached to the extracellular domain of cell-sur-
face glycoproteins on live cells. Following enzymatic diges-
tion, biotinylated glycopeptides are enriched by affinity
chromatography using immobilized streptavidin. Finally,
the enzyme N-glycosidase F (PNGaseF), which cleaves
between the innermost GlcNAc and the asparagine residue,
selectively releases the formerly N-glycosylated peptides
for subsequent analysis by high mass accuracy mass
spectrometry analysis. Overall, this strategy provides for
highly specific identification of cell-surface N-glycopro-
teins, including transmembrane, glycophosphatidylinosi-
tol (GPI)-anchored, and extracellular matrix, with minimal
contamination from intracellular membrane proteins
(Wollscheid et al., 2009; Bausch-Fluck et al., 2015; Boheler
et al., 2014).
Proteins identified in this workflow are confidently as-
signed as originating from the cell surface if they are iden-
tified by at least one peptide containing a deamidated
asparagine (resulting from PNGaseF cleavage) within the
conserved sequence motif for N-glycosylation (NxS/T/C),
although the majority of N-glycoproteins identified
here are represented by multiple peptides (Table S1). An
annotated tandem mass spectrometry (MS/MS) spectrum
for a peptide derived from SLC10A1, illustrating the
deamidation within the sequence motif is shown in Fig-
ure 2B. Using the above criteria, 300 cell-surface N-glyco-
proteins, including 66 cluster of differentiation (CD)
molecules were identified on primary human hepatocytes
(Figure 2C). A complete list of all N-glycoproteins that
were identified is provided in Table S1. Functional annota-
tion using DAVID reveals that of the 300 N-glycoproteins
identified, 292 are classified as glycoproteins and 228
as transmembrane proteins (Figure S1A). Gene ontology
analyses revealed, as expected, that functions typically
associated with transmembrane proteins, including recep-
tors, signal transduction, and transporter activity, were
highly represented (Figure S1B).
Identification of N-Glycoproteins That Are Enriched
in Primary Hepatocytes
As discussed above, the ability to generate hepatocyte-like
cells from iPSCs has enabled the modeling of inborn errors
of hepatic metabolism in culture (Cayo et al., 2012; Rashid
et al., 2010). However, heterogeneity in the differentiated
cell population can complicate the interpretation of re-
sults. We reasoned that relatively homogeneous popula-
tions of cells could be generated by FACS using antibodies
that recognize cell-surface N-glycoproteins that are
enriched in hepatocytes. To date, Asialoglycoprotein Re-
ceptor 1 (ASGR1) has been used for hepatocyte enrichment
(Basma et al., 2009; Peters et al., 2016). Although ASGR1 is
highly expressed in the liver, it is also abundant in the gall
bladder (Wilhelm et al., 2014). Moreover, studies of he-
matopoietic cells have revealed that increasing the reper-
toire of cell-surface proteins available for sorting promotes
specificity (Lanier et al., 1983; Spangrude et al., 1988). We,
therefore, sought to identify additional proteins whose
presence on the hepatocyte cell surface may facilitate the
production of homogeneous populations of hepatocyte-
like cells from differentiating iPSCs.
We reasoned that N-glycoproteins whose expression
was robust and restricted to hepatocytes would be the
most suitable for purifying hepatocytes from iPSCs. An
extensive searchable database, the Cell Surface Protein
Atlas (Atlas), which presents the surfaceome of a broad va-
riety of 47 human cell types, has recently been made
available (Bausch-Fluck et al., 2015). We exploited this
database along with surfaceome of human embryonic
stem cells (ESCs) and iPSCs to obtain the frequency of
detection of each protein identified in primary hepato-
cytes (Figure 2C) (Boheler et al., 2014). Protein distribu-
tion frequency ranged from proteins detected only in
primary hepatocytes to those whose presence was ubiqui-
tous. As with any mass spectrometry, failure to identify a
particular protein does not irrefutably confirm the
absence of that protein from the surface of that cell
type. Rather, this resource is most valuable as a first step
to eliminate proteins that are observed across many cell
types and to narrow the focus to proteins that may be
informative of a cell type of interest. Of the 300 N-glyco-
proteins identified, 52 were detected only in primaryhepatocytes and 40 of those were annotated as transmem-
brane or GPI-anchored proteins (Figure 2C; Table S1). As
our goal was to identify cell-surface N-glycoproteins that
could be used for live cell sorting, we focused our subse-
quent analyses on these 40 hepatocyte-enriched trans-
membrane or GPI-anchored proteins (Table 1).
A Subset of Hepatocyte-Enriched N-Glycoproteins Are
Induced during the Differentiation of Human
Pluripotent Stem Cells into Hepatocyte-like Cells
To further narrow the 40 candidates down to thosewith the
most potential for sorting iPSC-derived hepatocyte-like
cells, we focused on those N-glycoproteins for which
mRNA levels are most robustly expressed in iPSC-derived
hepatocyte-like cells and induced during the final stages
of differentiation when the hepatocytes reach relative
maturity (Figure 1). We have previously described a proto-
col for the efficient and reproducible differentiation of hu-
man ESCs and iPSCs into hepatocyte-like cells using
defined culture conditions (Si-Tayeb et al., 2010a;Mallanna
and Duncan, 2013) The procedure recapitulates the
stages of hepatocyte differentiation that occur during
embryogenesis. Definitive endoderm is produced by
day 5, endoderm is converted to a hepatic fate by day 10,
fetal hepatocyte-like cells are formed by day 15, and cells
with more mature hepatocyte characteristics are generated
by day 20 (Mallanna and Duncan, 2013; Si-Tayeb et al.,
2010a; Yu et al., 2012). We recently established mRNA pro-
files from each stage of the differentiation process using
oligonucleotide arrays (Si-Tayeb et al., 2010a; Delaforest
et al., 2011). Using this approach, we examined the te-
mporal expression pattern of mRNAs encoding the 40
hepatocyte-enriched cell-surface N-glycoproteins during
differentiation. The mRNA levels encoding six of the pro-
teins (CLRN3, KLB, SLC22A7, AADAC, SLC10A1, and
UGT2B4) were found to be enriched R8-fold either by
day 15 or day 20, coincident with when the cells establish
hepatocyte function (Figure 3A). We finally used a genetic
approach to examine whether the increases in these
mRNA levels was due to expression in hepatocytes (Fig-
ure 3B). The transcription factor HNF4A is essential for
hepatocyte differentiation and when HNF4A is depleted,
PSCs are incapable of adopting a hepatic fate (Delaforest
et al., 2011; Li et al., 2000; Parviz et al., 2003).We predicted
that if the mRNAs encoding the candidate N-glycoproteins
were selectively expressed in ESC-derived hepatocytes, the
relative abundance of these mRNAs should be depleted in
the absence of HNF4A. As shown in Figure 3B, in contrast
to day 20 hepatocytes derived from control ESCs in which
mRNAs encoding the six N-glycoproteins were readily
detected by oligonucleotide array analyses, these same
mRNAs were undetectable in hepatocytes derived from
HNF4A-depleted ESCs.Stem Cell Reports j Vol. 7 j 543–556 j September 13, 2016 545
Figure 2. Identification of N-Linked Glycoproteins in Primary Hepatocytes by Cell Surface Capture Technology
(A) Illustration outlining the CSC-Technology.
(B) Left: Annotated MS/MS spectrum of a representative peptide from SLC10A1 that was identified in primary hepatocytes by
CSC-Technology. Two identified sites of N-glycosylation (N115) are indicated. Right: An illustration of the transmembrane topology of
SLC10A1 highlighting the extracellular peptide identified by CSC-Technology, including sites of N-glycosylation (also see Figure S2).
Image generated using Protter (Omasits et al., 2014).
(legend continued on next page)
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SLC10A1, CLRN3, and AADAC Are Co-expressed in a
Subset of iPSC-Derived Hepatocytes
Of the six N-glycoproteins that were selected as hepatocyte
markers, commercially available antibodies that were
compatible with FACS were available for SLC10A1,
CLRN3, and AADAC. Representative MS/MS spectra and
peptide sequences from the CSC-Technology analyses are
provided for each of these proteins (Figure S2) and all cor-
responding peptide details are in Table S1. Oligonucleotide
array analyses performed on differentiating ESCs indicated
that the mRNAs encoding these proteins were induced as
the cells approached maturity (day 20; Figure 3A). We
therefore attempted to confirm these expression profiles
on independent differentiations of iPSCs by qRT-PCR. As
expected, like Albumin and ASGR1, which were used as
markers of differentiation, SLC10A1, CLRN3, and AADAC
mRNAs were close to undetectable in PSCs (day 0), defini-
tive endoderm cells (day 5), and hepatic progenitor cells
(day 10) (Figure 3C). Consistent with the oligonucleotide
array data, we observed a large induction of CLRN3
mRNA at day 15, which continued through day 20.
SLC10A1 and AADAC transcript levels remained low at
day 15 then increased substantially by day 20 of differenti-
ation (Figure 3C). Although SLC10A1, CLRN3, and AADAC
mRNAs were reproducibly induced as the iPSC-derived he-
patocytes entered a maturation phase, it is important to
note that a comparison of the mRNA levels found in
iPSC-derived hepatocytes with those found in primary
hepatocytes revealed them to be significantly lower in the
iPSC- and ESC-derived cells (Figure 3D). Similar results
were obtained when qRT-PCR was performed on hepato-
cyte-like cells derived from either H1 (WA01) or H9
(WA09) human ESCs (Figure S3A).
We reasoned that the relatively low levels of mRNAs en-
coding SLC10A1, CLRN3, and AADAC observed in the
iPSC-derived hepatocytes could be due to low expression
throughout the entire population of cells or alternatively
that expression is restricted to a subpopulation. To distin-
guish between these possibilities, we examined the cellular
distribution of SLC10A1, CLRN3, and AADAC proteins in
iPSC-derived hepatocytes by immunocytochemistry and
live cell flow cytometry (Figure 4). Confocal imaging of
iPSC-derived hepatocytes revealed that the target proteins
were uniformly detected throughout the cell membranes
but were present on a subpopulation of differentiated cells
(Figure 4A). Next, flow cytometry was used to quantify the
percent positive population. These analyses revealed that(C) Graphical representation of the distribution of proteins identified
type documented in the Cell Surface Protein Atlas, which consists of 4
the surface of primary hepatocytes described in the current study. Eac
was reported as present in the cell line, whereas blue indicates that i
lowest at the top and highest at the bottom. The identity of each pr20%–25% of the total population was positive for each of
these cell-surface N-glycoproteins (Figure 4B). To confirm
the identity of the SLC10A1-, CLRN3-, and AADAC-posi-
tive cells, co-staining experiments using an antibody that
recognizes the hepatocyte transcription factor HNF4A
were performed. By day 20 of differentiation, >90% of cells
expressed HNF4A (Figure 4C). However, while nearly all of
the SLC10A1-, CLRN3-, or AADAC-positive cells were also
positive for HNF4A, only a subpopulation of HNF4A-posi-
tive cells were positive for SLC10A1, CLRN3, or AADAC
(Figure 4C; note that fixation conditions required to detect
HNF4A resulted in non-specific binding of the anti-AADAC
antibody). Pairwise co-staining revealed that SLC10A1,
CLRN3, and AADAC are expressed on the same subpopula-
tion of iPSC-derived hepatocytes (Figure S3B).
All these experiments were performed using a single iPSC
line (iPSC-K3) that was derived from foreskin fibroblasts as
we have described previously (Si-Tayeb et al., 2010b). To
exclude the possibility that the heterogeneous expression
of SLC10A1, CLRN3, and AADAC reflected any peculiarity
of K3 cells, we repeated our analyses on hepatocytes
derived from an independent iPSC line (SV20) that was
generated from peripheral blood mononuclear cells from
an independent donor (Yang et al., 2015). Similar to using
K3 iPSCs, SLC10A1, CLRN3, andAADACwere co-expressed
in 25% of SV20 iPSC-derived hepatocytes (Figure S3C).
Based on these results, we conclude that SLC10A1,
CLRN3, and AADAC are expressed on a common sub-
population of iPSC-derived hepatocytes. Since ASGR1
has been used by others to purify iPSC-derived
hepatocytes by FACS, we compared the distribution of
ASGR1 protein with SLC10A1, CLRN3, and AADAC by
immunostaining. Although ASGR1 was more broadly ex-
pressed, all SLC10A1, CLRN3, and AADAC positive cells
also expressed ASGR1 (Figure S4). These results confirm
that although the vast majority of cells derived from the
iPSCs have adopted a hepatic fate and are HNF4A positive,
expression of mature hepatic markers is heterogeneous.
SLC10A1 Purified iPSC-Derived Hepatocytes
Demonstrate Improved Hepatic Phenotype, Depletion
of Pluripotent Cell Markers, and Increased
Homogeneity
Immunohistochemistry performed on human liver
sections has revealed that SLC10A1, CLRN3, and AADAC
are expressed on >75% of the liver’s hepatocytes (data
provided by the Human Protein Atlas; Uhlen et al., 2010;in primary hepatocytes. Each column represents an individual cell
9 different cell types. The last column shows proteins identified on
h row represents a single protein. A yellow bar indicates the protein
t was not observed. The frequency of distribution of each protein is
otein in the order presented is provided in Table S1.
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Table 1. 40 Cell Surface N-Glycoproteins Identified as
Hepatocyte-Restricted Compared with 49 Other Human Cell
Types
Gene Symbol Protein Name Type
AADAC arylacetamide deacetylase TM
ABCA6 ATP-binding cassette sub-family A
member 6
TM
ABCB11 bile salt export pump TM
ABCC6 multidrug resistance-associated protein 6 TM
ABCG8 ATP-binding cassette sub-family G
member 8
TM
ANO1 anoctamin-1 TM
AQP9 aquaporin-9 TM
ART4 ecto-ADP-ribosyltransferase 4 GPI
ASGR1 asialoglycoprotein receptor 1 TM
ASGR2 asialoglycoprotein receptor 2 TM
C8A complement component C8 alpha chain TM
CDHR5 cadherin-related family member 5 TM
CLRN3 Clarin-3 TM
FAM151A protein FAM151A TM
FOLH1 glutamate carboxypeptidase 2 TM
HFE2 hemojuvelin GPI
KLB b-klotho TM
NPC1L1 Niemann-Pick C1-like protein 1 TM
SLC10A1 sodium/bile acid cotransporter TM
SLC1A2 excitatory amino acid transporter 2 TM
SLC22A1 solute carrier family 22 member 1 TM
SLC22A3 solute carrier family 22 member 3 TM
SLC22A7 solute carrier family 22 member 7 TM
SLC22A9 solute carrier family 22 member 9 TM
SLC2A8 solute carrier family 2, facilitated glucose
transporter member 8
TM
SLC39A5 zinc transporter ZIP5 TM
SLC46A3 solute carrier family 46 member 3 TM
SLC6A12 sodium- and chloride-dependent betaine
transporter
TM
SLCO1B1 solute carrier organic anion transporter
family member 1B1
TM
SLCO1B3 solute carrier organic anion transporter
family member 1B3
TM
Table 1. Continued
Gene Symbol Protein Name Type
TFR2 transferrin receptor protein 2 TM
TM4SF4 transmembrane 4 L6 family member 4 TM
TM4SF5 transmembrane 4 L6 family member 5 TM
TMEM110 store-operated calcium entry regulator
STIMATE
TM
TMPRSS6 transmembrane protease serine 6 TM
TMUB1 transmembrane and ubiquitin-like
domain-containing protein 1
TM
UGT1A4 UDP-glucuronosyltransferase 1-4 TM
UGT2B15 UDP-glucuronosyltransferase 2B15 TM
UGT2B4 UDP-glucuronosyltransferase 2B4 TM
UGT2B7 UDP-glucuronosyltransferase 2B7 TM
TM, transmembrane; GPI, glycophosphatidylinositol.
548 Stem Cell Reports j Vol. 7 j 543–556 j September 13, 2016Uhle´n et al., 2015). The broad distribution of these cell-sur-
face proteins throughout the hepatic parenchyma implies
that they could facilitate FACS-based purification of a
homogeneous population of iPSC-derived cells with hepa-
tocyte characteristics. To test this hypothesis, we used
antibodies to SLC10A1, CLRN3, or AADAC and FACS to
collect populations of iPSC-derived hepatocytes at day 20
of differentiation and subsequently measured abundance
of characteristic hepatic mRNAs in the sorted cells by
qRT-PCR. Gating parameters for FACS for SLC10A1-posi-
tive iPSC-derived hepatocytes is shown in Figure S5A. As
shown in Figure 5, SLC10A1 mRNA was enriched in
SLC10A1-positive cells by 3-fold compared with the
levels found in pre-sorted cells and was close to undetect-
able in the SLC10A1-negative population. Analyses of
mRNAs encoding CLRN3, AADAC, HNF4A, albumin,
ASGR1, APOA1, and AFP by qRT-PCR revealed that each
of these hepatocyte markers was significantly enriched in
the SLC10A1-positive population compared with both
the SLC10A1-negative cells and the pre-sorted cells (Fig-
ure 5; Figure S5B). Similar results were obtained when
FACS was performed to collect CLRN3- and AADAC-posi-
tive cells (Figures S5C and S5D).
Finally, we examined whether FACS selection of
SLC10A1-positive iPSC-derived hepatocytes improved
overall hepatic characteristics and homogeneity. Four inde-
pendent iPSC differentiations were performed until
day 20, and the cells were subjected to FACS using an
anti-SLC10A1 antibody. Pre-sort, SLC10A1-positive, and
SLC10A1-negative populations were then subjected to
transcriptome analyses using oligonucleotide arrays. Cell
profiles were compared using CellNet (Cahan et al., 2014;
Figure 3. Selection of Cell Surface Proteins for Purifying iPSC-Derived Hepatocyte-like Cells
(A) Heatmap showing enrichment of six transcripts encoding hepatocyte-restricted cell surface glycoproteins (CLRN3, KLB, SLC22A7,
AADAC, SLC10A1, and UGT2B4) during the differentiation of human ESCs to hepatocyte-like cells. Published oligonucleotide array data
from biological replicates at days 0, 5, 10, 15, and 20 of differentiation were analyzed (Si-Tayeb et al., 2010a; Delaforest et al., 2011). Fold
enrichment of the six transcripts between days 10 and 15 or days 15 and 20 is given next to the heatmap.
(B) Published oligonucleotide expression data were used to examine transcript levels encoding CLRN3, KLB, SLC22A7, AADAC, SLC10A1,
and UGT2B4 in hepatocyte-like cells generated from wild-type ESCs and ESCs in which HNF4A is depleted (Delaforest et al., 2011). Fold
decrease in the level of transcripts following HNF4A depletion is given next to the heatmap.
(C) Bar graphs of qRT-PCR results showing levels of mRNAs encoding cell-surface proteins SLC10A1, CLRN3, AADAC, ASGR1, and albumin on
days 0, 5, 10, 15, and 20 of differentiation of iPSCs into hepatocyte-like cells. Data are represented as means ± SEM of biological replicates
(n = 3). Significance of enrichment in day 20 cells compared with day 15 cells was determined by Student’s t test, *p < 0.05.
(D) Bar graphs of qRT-PCR results showing relative expression levels of mRNAs encoding SLC10A1, CLRN3, AADAC, ASGR1, and albumin in
iPSC-derived hepatocyte-like cells in comparison with primary hepatocytes (see also Figure S3A). Data are represented as means ± SEM of
biological replicates (n = 3). Significance was determined by Student’s t test, *p < 0.05.Morris et al., 2014), which is a computational platform
designed to define the similarity between stem-cell-derived
cell types and their endogenous counterparts by com-
paring the expression levels of gene regulatory networks
(Figure 6A; Table S2). A higher classification score indicates
an increase in the probability that expression of a gene reg-
ulatory network resembles that of a target tissue (Cahanet al., 2014; Morris et al., 2014). As expected, in the pre-
sorted population, the differentiated cells most closely
resembled liver compared with 14 other tissue types. Sur-
prisingly, however, pluripotent cell characteristics were
also predominant in the pre-sorted population, suggesting
that the cultures contained cells that had failed to differen-
tiate or had retained expression of PSCmarkers (Figure 6A).Stem Cell Reports j Vol. 7 j 543–556 j September 13, 2016 549
Figure 4. A Subpopulation of iPSC-Derived Hepatocyte-like
Cells Express SLC10A1, CLRN3, and AADAC
(A) Confocal micrographs showing the results of immunocyto-
chemistry to detect expression of cell-surface proteins SLC10A1,
550 Stem Cell Reports j Vol. 7 j 543–556 j September 13, 2016When the character of the SLC10A1-expressing cell
population was examined, it revealed that the cells had
substantially increased hepatic characteristics and reduced
pluripotent cell characteristics. In contrast to the SLC10A-
positive population, the SLC10A1-negative population lost
hepatic characteristics and retained PSC characteristics.
We confirmed that the SLC10A1-positive cells more
closely resembled hepatocytes comparedwith the unsorted
and SLC10A1-negative cells by examining the levels of
mRNAs encoding 39 proteins that are highly enriched in
liver tissue (Ge et al., 2005; Si-Tayeb et al., 2010a). These
hepatic mRNAs were consistently enriched in the
SLC10A1-positive cell population compared with unsorted
and negative cell populations (Figure 6B; Table S3).
Although hepatocyte-like cells generated from indepen-
dent differentiations looked morphologically indistin-
guishable (Figure S6A), we observed substantial variation
in expression of hepatic markers among samples, confirm-
ing heterogeneity in the extent of maturation (Figures 6B
and 6C; Table S3). However, in contrast to unsorted cells,
the SLC10A1-positive population shows uniform levels of
hepatic mRNAs among independent differentiations (Fig-
ures 6B and 6C; Table S3). These data demonstrate that
sorting hepatocyte-like cells using an anti-SLC10A1 anti-
body facilitates the efficient purification of a homogeneous
population of cells with hepatocyte characteristics.DISCUSSION
Hepatocyte-like cells generated from iPSCs can be used to
model liver development and disease, for toxicity studies,
and potentially could offer a source of hepatocytes for
cell therapy (Rashid et al., 2010; Delaforest et al., 2011;
Cayo et al., 2012; Fox et al., 2014). While the promise of
such cells is exciting, improvements to the existing differ-
entiation protocols are necessary to obtain a homogeneous
and mature population of hepatocytes whose function re-
capitulates the native parenchymal cells of the liver. In
the current study, we addressed the issue of heterogeneityCLRN3, and AADAC in iPSC-derived hepatocyte-like cells (green).
Nuclei are identified by DAPI staining (blue) (see also Figures S3B
and S3C). Scale bars, 100 mm.
(B) FACS histogram plots of iPSC-derived hepatocyte-like cells
stained with primary antibodies against proteins SLC10A1, CLRN3,
and AADAC and corresponding phycoerythrin (PE) conjugated
secondary antibody are shown. Cells stained with PE conjugated
secondary antibody only are used as control.
(C) Confocal micrographs showing the results of immunocyto-
chemistry to detect expression of HNF4A (red) and cell-surface
proteins SLC10A1, CLRN3, and AADAC (green) in iPSC-derived
hepatocyte-like cells (see also Figure S4). Nuclei are identified by
DAPI staining (blue). Scale bars, 100 mm.
Figure 5. A Subpopulation of iPSC-
Derived Hepatocyte-like Cells that
Express SLC10A1 Is Enriched for Several
Liver-Specific Markers
iPSC-derived hepatocyte-like cells were
sorted by FACS using an antibody against
SLC10A1 (see also Figure S5A). Bar graphs
show qRT-PCR analysis to determine the
levels of mRNAs encoding the liver-enriched
proteins (HNF4A, albumin, ASGR1, APOA1,
AFP) and cell-surface proteins (SLC10A1,
CLRN3, AADAC) in the SLC10A1-positive
and -negative cell fractions. Levels of
mRNAs were compared with the pre-sorted
cell population that is set to 1.0 (see also
Figures S5B–S5D). To avoid any bias intro-
duced by the sorting process, the pre-sort
population was collected as the gated viable
cell fraction after passing through the FACS.
Data are represented as means ± SEM from
sorting performed on three independent
differentiations (n = 3). Significance of
enrichment in the SLC10A1-positive popu-
lation compared with the pre-sorted popu-
lation was determined by Student’s t test,
*p < 0.05.associated with the differentiation procedure by identi-
fying cell-surface markers that facilitate the purification
of homogeneous cell populations.
Traditionally, identification and characterization of
cell-surface proteins heavily relied on the availability of
antibodies. In such cases, the need for well-characterized
antibodies invariably biases study design to focus on CD
antigens that are defined by their interaction with mono-
clonal antibodies (Lanier et al., 1983; Spangrude et al.,
1988). Such focus, while not without value, limits the po-
tential repertoire of target proteins that could be used for
cell sorting. In contrast, mass spectrometry offers the
advantage of being able to identify, characterize, and
quantify cell-surface proteins independently of the avail-
ability of suitable antibodies. Specifically in the case of
the CSC-Technology, the approach exploits the fact that
the majority of cell-surface proteins are glycosylated
to enable specific detection of transmembrane, GPI-
anchored, and extracellular matrix proteins. Moreover,
as secreted proteins are also commonly modified by
N-linked glycosylation, the CSC-Technology can also
detect proteins that are transiting through the secretory
pathway, especially if they are abundant. This explains
why 71 of 300 proteins identified in our study are
annotated as secreted by DAVID. Examples include
Apolipoprotein B-100, a-1-antitrypsin, and Coagulationfactor V, all of which are abundant serum factors that
are known to be secreted by hepatocytes. Although the
focus of the current study was to identify proteins that
can be used to sort hepatocytes that are derived from
iPSCs, the availability of an extensive catalog of proteins
present on the hepatocyte cell surface should also be valu-
able for the study of hepatocyte biology and liver disease.
The biological roles of many of the identified proteins
within the hepatocyte are poorly understood. This in-
cludes one of our target proteins Clarin 3, which is a
multi-pass transmembrane protein that has restricted
cell distribution among the cell types within the Atlas.
While the function of this protein is poorly understood,
mutations in a paralog, Clarin 1, have been associated
with Usher syndrome, which causes loss of vision and
hearing (Joensuu et al., 2001). In addition to providing
tools to advance our understanding of liver cell biology,
the expanding database of hepatocyte cell-surface pro-
teins should facilitate the identification of receptors
involved in infectious disease. In this regard, SLC10A1
(also known as NTCP) has recently been described as a re-
ceptor for the hepatitis B and D viruses (Yan et al., 2012).
It is, therefore, likely that receptors for known and
emerging hepatotropic infectious agents will be present
within the catalog of hepatocyte cell-surface proteins we
have described.Stem Cell Reports j Vol. 7 j 543–556 j September 13, 2016 551
Figure 6. SLC10A1-Positive iPSC-Derived Hepatocyte-like Cells
Are Enriched for Hepatic Gene Regulatory Genes and Sorting
Them Minimizes Variability Associated with Differentiation
(A) Microarray analysis was performed on different cell fractions
of iPSC-derived hepatocyte-like cells sorted for expression
of SLC10A1. CellNet classification heatmap showing enrichment of
liver-specific GRN genes and depletion of ESC-specific GRN genes in
the positive sort cell fraction compared with the pre-sort and
negative sort cell fractions. Classification scores corresponding to
the ESC- and liver-specific GRN genes from the heatmap are
presented below the heatmap. Classification scores for different
target tissue GRNs represented in the heatmap are provided in
Table S2. Microarray data on the pre-sort, positive sort, and
negative sort cell fractions from four independent differentiations
were used for CellNet analysis (n = 4) (see also Figure S6).
(B) Heatmap showing expression levels of 39 liver signature genes
in pre-sort, positive sort, and negative sort cell fractions. Probe
sets of 39 liver signature genes and the corresponding raw signal
values in different cell fractions are provided in Table S3 in the
same order as in the heatmap. Microarray data on the pre-sort,
positive sort, and negative sort cell fractions from four indepen-
dent differentiations were used to generate the heatmap (n = 4).
(C) Line diagram showing raw signal values of the top ten abundant
transcripts selected from 39 liver signature genes in pre-sort and
SLC10A1-positive sort cell fractions of hepatocyte-like cells. Signal
values of GAPDH transcript served as internal control. Microarray
data from four independent differentiations were used to generate
the line diagram (n = 4) (see also Figure S6).
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human liver/hepatocytes are limited. Several proteomic
studies have focused on the identification of N-glycopro-
teins in liver tissue extracts (Sun et al., 2014; Chen et al.,
2009; Zhu et al., 2014). Although these approaches provide
important information regarding the repertoire of proteins
present in the liver, they were not designed to specifically
identify cell-surface proteins. Importantly, using whole-
liver tissue extract limits the specificity of markers due to
the presence of a mixed cell population in the sample. In
contrast, Ducret et al. (2015) used a cell-surface capture
approach to identify 147 cell-surface N-glycoproteins in
primary humanhepatocytes. Of the 300 proteins identified
in our analyses, Ducret et al. also identified 114 and 186 are
unique to our study. Differences in technical approach,
including the number of hepatocytes analyzed, likely
explain the differences between these two studies. Of
note, CLRN3, KLB, SLC22A7, AADAC, SLC10A1, and
UGT2B4 were not described as liver-enriched proteins by
Ducret et al., which would imply that this screen was not
saturated.
The ability to use cell-surface proteins to specifically sort
iPSC-derived hepatocyte-like cells is currently limited. The
liver-specific cell-surface protein ASGR1 has been used to
sort human ESC- and iPSC-derived hepatocyte-like cells
(Basma et al., 2009; Peters et al., 2016). These studies
demonstrated enrichment of hepatic phenotype in ASGR1-
positive cells by performing transcriptional analysis and
functional assays. Although we identified ASGR1 on the
cell surface of primary hepatocytes, its transcript expres-
sion pattern during hPSC differentiation into hepatocyte-
like cells did not meet the stringent enrichment criteria
we required to select the final candidate proteins for our
studies. More recently, microRNA switches have been
used to enrich for a desired population of hepatocyte-like
cells generated by directed differentiation (Miki et al.,
2015). In this approach, reporter mRNAs containing target
sequences for miRNAs expressed in the desired cell type are
transfected, and diminished reporter expression enables
sorting of the target cell population. Although useful,
transfection adds technical variability, and differences in
transfection efficiency of reporter mRNAs could contribute
to differences in the cell types sorted from distinct biolog-
ical samples. With this in mind, we believe the use of
endogenous proteins that are accessible to affinity reagents
for live cell sorting will prove most apt for the selection of
homogeneous cell populations suitable for research and
clinical applications.
Finally, we provide evidence that cell sorting using anti-
bodies to either SLC10A1, CLRN3, or AADAC can improve
the quality of hepatocyte-like cells generated from iPSCs.
Cell populations resulting from positive selection based
on these markers displayed higher levels of characteristic
hepatic mRNAs. Importantly, a comparison of marker
expression among four independent differentiations re-
vealed that the cells sorted based on the presence of
SLC10A1 had substantially lower variation in expression
of characteristic mRNAs than the unsorted population.
This implies that sorting cells using SLC10A1, CLRN3, or
AADAC will improve comparisons among control and pa-
tient iPSC-derived hepatocytes. Minimizing heterogeneity
within cultures of iPSC-derived cells should facilitate our
ability to compare and interpret data resulting from hepa-
tocytes generated from iPSCs that model metabolic liver
disease. Until now, because of variations with differentia-
tion, analyses of disease phenotypes have been limited to
patients with Mendelian disorders. However, the ability
to generate homogeneous populations of iPSC-derived
hepatocytes should facilitate analyses of complex pheno-
types. For example, several common allelic variations
that associate with lipid traits have been identified by
genome-wide association studies (Teslovich et al., 2010).
Producing homogeneous populations of iPSC-derived he-
patocytes from either patient iPSCs or iPSCsmodified using
genome editing approaches could facilitate direct testing of
a specific variant’s contribution to levels of secreted lipid.
Use of recombinant laminins as substrates have recently
been shown to improve cell organization, cell function,
and phenotype of humanESC-derived hepatocyte-like cells(Cameron et al., 2015). Using data published by Cameron
et al. (2015), we compared the liver-enriched gene regu-
latory network (GRN) of SLC10A1-positive cells with hepa-
tocyte-like cells differentiated on recombinant laminin
substrates. The GRN of SLC10A1-positive cells appeared
to be comparable with hepatocyte-like cells differentiated
on recombinant laminin substrates, although we acknowl-
edge that differences in experimental protocol may intro-
duce some error into this comparative analysis (Figure S6B).
Importantly, however, SLC10A1-positive cells from inde-
pendent differentiations exhibited less variation in the
liver GRN compared with independent differentiations of
hepatocyte-like cells on recombinant laminin substrates,
which is consistent with the belief that sorting using
such cell-surface markers can enhance the homogeneity
of the hepatocyte-like cell population (Figure S6B). These
analyses also suggest that by combining approaches,
further advances in the quality and homogeneity of iPSC-
derived hepatocytes when compared with fresh hepato-
cytes could be obtained (Figure S6C).
In conclusion, our study provides an expanded dataset of
cell-surface N-glycoproteins on primary hepatocytes. We
expect this resource, in conjunction with the bioinformat-
ics workflow that includes the evolving Atlas as a platform
to identify cell-type-restricted proteins, will be valuable for
researchers investigating liver biology and pathophysi-
ology. Importantly, we establish the functional utility of
this resource andworkflow by identifying three cell-surface
N-glycoproteins capable of selecting a homogeneous
subpopulation of iPSC-derived hepatocyte-like cells that
display enhanced hepatic characteristics.EXPERIMENTAL PROCEDURES
Cell Culture
Procedures for the culture of human iPSCs and their differentiation
into hepatocyte-like cells have been described in detail previously
(Mallanna and Duncan, 2013). The use of human cells was
approved by the Medical College of Wisconsin Stem Cell Research
Oversight and Institutional Safety Board committees.
CSC-Technology
Approximately 100 million primary human hepatocytes were
subjected to CSC-Technology workflow as reported previously
(Wollscheid et al., 2009; Gundry et al., 2012). Frozen primary
human hepatocytes (Hu8176, Hu1443, Hu1460, and Hu1736)
were obtained from Life Technologies/Thermo Fisher Scientific.
Additional details are provided in Supplemental Experimental
Procedures.
qRT-PCR Analysis
RNA was isolated from iPSC-derived hepatocyte-like cells and
primary human hepatocytes using the RNeasy mini or micro kits
(QIAGEN). Genomic DNA was removed using 1 ml of RNase-freeStem Cell Reports j Vol. 7 j 543–556 j September 13, 2016 553
DNaseI per 5 mg of RNA. First-strand cDNA was synthesized using
Moloney murine leukemia virus reverse transcriptase with dNTPs
and random hexamer primers. qRT-PCR was performed using
either StepOne Plus (Applied Biosystems/Thermo Fisher Scientific)
or CFX-384 real-time PCR machine (Bio-Rad) with PrimeTime
assays (Table S4) (Integrated DNA Technologies) following the
manufacturer’s protocols.
Immunostaining
For immunostaining cell-surface proteins (SLC10A1, CLRN3,
AADAC, and ASGR1), fixed, non-permeabilized cells were incu-
bated with antibodies against cell-surface proteins. For co-im-
munostaining for HNF4A, fixed non-permeabilized cells were
incubated with antibodies against cell-surface proteins first,
followed by fixing again, permeabilization, and incubation with
HNF4A antibody. Finally, cells were incubated with appropriate
secondary antibodies and nuclear stain DAPI to complete the
staining. Additional details of the immunostaining protocol along
with relevant antibody information are provided in the Supple-
mental Experimental Procedures.
Fluorescent-Activated Cell Sorting
A subpopulation of iPSC-derived hepatocyte-like cells expressing
SLC10A1, CLRN3, and AADAC were sorted using the fluorescent-
activated cell sorting (FACS) protocol described in detail in the
Supplemental Experimental Procedures. Primary antibodies used
were SLC10A1 (Aviva, ARP42097_P050), CLRN3 (Thermo Fisher
Scientific, PA5-26137), and AADAC (LSBio, LS-C155827). Mouse
monoclonal antibodies (B6E11 and C3B6) were generated
commercially (Biomatik) to detect an external epitope on human
SLC10A1 (YSRGIYDGDLKDKVPY). Hybridomas and the corre-
sponding monoclonal antibodies have been made available to
investigators through the Developmental Studies Hybridoma
Bank created by the NICHD and maintained at the University of
Iowa (http://dshb.biology.uiowa.edu/Welcome?search=slc10A1).
Oligonucleotide Array Analysis
Total RNA from different FACS-sorted fractions of iPSC-derived
hepatocyte-like cells (pre-sort, SLC10A1 positive sort, SLC10A1
negative sort) from four independent differentiations was isolated
using an RNeasy plus micro kit (QIAGEN). Biotinylated cRNA was
generated from 500 ng of total RNA using the 30 IVT Plus kit and
hybridized to GeneChip Human Genome U133 Plus 2.0 Arrays
(Affymetrix). Images were acquired using a GeneChip Scanner
3000 (Affymetrix), and data analysis was performed using the
Partek Genomic Suite Statistical Analysis Software (Partek).
ACCESSION NUMBERS
All original gene array CEL files are available from theGene Expres-
sion Omnibus (GEO) accession number GEO: GSE80279.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, six figures, and four tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
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